Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
Mutations in the tyrosine kinase (TKD) domain of the epidermal growth factor receptor (EGFR) are involved in the unfavorable therapeutic response through resistance to targeted molecular therapy. Data from the clinical experience of non-small cell lung carcinoma (NSCLC) treatment demonstrate the ben...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Media Med Publicis
2022-09-01
|
| Series: | Modern Medicine |
| Subjects: | |
| Online Access: | https://medicinamoderna.ro/wp-content/uploads/2022/09/Targeting-EGFR-Exon-20-Insertion-mutated-Cancers-%E2%80%93-New-Perspectives-in-Head-and-Neck-Cancers.pdf |
| _version_ | 1798031349867610112 |
|---|---|
| author | Camil Ciprian MIRESTEAN Roxana Irina IANCU Dragos Teodor IANCU |
| author_facet | Camil Ciprian MIRESTEAN Roxana Irina IANCU Dragos Teodor IANCU |
| author_sort | Camil Ciprian MIRESTEAN |
| collection | DOAJ |
| description | Mutations in the tyrosine kinase (TKD) domain of the epidermal growth factor receptor (EGFR) are involved in the unfavorable therapeutic response through resistance to targeted molecular therapy. Data from the clinical experience of non-small cell lung carcinoma (NSCLC) treatment demonstrate the benefit of tyrosine kinase inhibitors (TKIs) in cases of EGFR mutation. The next generation sequencing technique (NGS) allows the identification of hot spots involved in mutations, exon 20 insertion being associated with the unfavorable response. Exon 20 insertions are more common in head and neck squamous cell carcinoma (HNSCC) compared to NSCLC, which could explain a resistance to targeted therapy in head and neck cancers. Taking into account the data reported in the NSCLC, Amivantamab, a bi-specific EGFR-MET antibody with potential immune cell modulation of activity, but also other innovative therapies validated in exon 20 EGFR mutation could be part of the therapy of sino-nasal cancer, but also of other HNSCC sites exon 20 mutant EFGR. |
| first_indexed | 2024-04-11T19:55:03Z |
| format | Article |
| id | doaj.art-a0380850f8dd42438fa8dad5ab31861e |
| institution | Directory Open Access Journal |
| issn | 1223-0472 2360-2473 |
| language | English |
| last_indexed | 2024-04-11T19:55:03Z |
| publishDate | 2022-09-01 |
| publisher | Media Med Publicis |
| record_format | Article |
| series | Modern Medicine |
| spelling | doaj.art-a0380850f8dd42438fa8dad5ab31861e2022-12-22T04:06:06ZengMedia Med PublicisModern Medicine1223-04722360-24732022-09-01293181185https://doi.org/10.31689/rmm.2022.29.3.181Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)Camil Ciprian MIRESTEAN0https://orcid.org/0000-0001-6212-8008Roxana Irina IANCU1Dragos Teodor IANCU2University of Medicine and Pharmacy of Craiova, Craiova, Romania“Gr. T. Popa” University of Medicine and Pharmacy, Iasi, Romania“Gr. T. Popa” University of Medicine and Pharmacy, Iasi, RomaniaMutations in the tyrosine kinase (TKD) domain of the epidermal growth factor receptor (EGFR) are involved in the unfavorable therapeutic response through resistance to targeted molecular therapy. Data from the clinical experience of non-small cell lung carcinoma (NSCLC) treatment demonstrate the benefit of tyrosine kinase inhibitors (TKIs) in cases of EGFR mutation. The next generation sequencing technique (NGS) allows the identification of hot spots involved in mutations, exon 20 insertion being associated with the unfavorable response. Exon 20 insertions are more common in head and neck squamous cell carcinoma (HNSCC) compared to NSCLC, which could explain a resistance to targeted therapy in head and neck cancers. Taking into account the data reported in the NSCLC, Amivantamab, a bi-specific EGFR-MET antibody with potential immune cell modulation of activity, but also other innovative therapies validated in exon 20 EGFR mutation could be part of the therapy of sino-nasal cancer, but also of other HNSCC sites exon 20 mutant EFGR.https://medicinamoderna.ro/wp-content/uploads/2022/09/Targeting-EGFR-Exon-20-Insertion-mutated-Cancers-%E2%80%93-New-Perspectives-in-Head-and-Neck-Cancers.pdfhead and neck cancerstkiegfrhnscclung cancernsclcamivantamabexon 20 |
| spellingShingle | Camil Ciprian MIRESTEAN Roxana Irina IANCU Dragos Teodor IANCU Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC) Modern Medicine head and neck cancers tki egfr hnscc lung cancer nsclc amivantamab exon 20 |
| title | Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC) |
| title_full | Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC) |
| title_fullStr | Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC) |
| title_full_unstemmed | Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC) |
| title_short | Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC) |
| title_sort | targeting egfr exon 20 insertion mutated cancers new perspectives in head and neck cancers lessons to learn from non small cell carcinoma nsclc |
| topic | head and neck cancers tki egfr hnscc lung cancer nsclc amivantamab exon 20 |
| url | https://medicinamoderna.ro/wp-content/uploads/2022/09/Targeting-EGFR-Exon-20-Insertion-mutated-Cancers-%E2%80%93-New-Perspectives-in-Head-and-Neck-Cancers.pdf |
| work_keys_str_mv | AT camilciprianmirestean targetingegfrexon20insertionmutatedcancersnewperspectivesinheadandneckcancerslessonstolearnfromnonsmallcellcarcinomansclc AT roxanairinaiancu targetingegfrexon20insertionmutatedcancersnewperspectivesinheadandneckcancerslessonstolearnfromnonsmallcellcarcinomansclc AT dragosteodoriancu targetingegfrexon20insertionmutatedcancersnewperspectivesinheadandneckcancerslessonstolearnfromnonsmallcellcarcinomansclc |